TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Galectin Therapeutics
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

Galectin Therapeutics reported Q3 2025 financial results, highlighting promising biomarker data from the NAVIGATE trial for belapectin in treating MASH cirrhosis. The company submitted data to the FDA and is seeking guidance on next steps, with encouraging results showing potential disease progression reduction.

Insights
PG   positive

Stable consumer staples company with consistent dividend growth, below-average historical valuation, strong free cash flow, and resilience during economic downturns


GALT   neutral

Mixed financial performance with reduced research expenses and net loss, but promising clinical trial results and ongoing FDA engagement suggest potential future growth